Efficacy of NMN for tinnitus
- Conditions
- tinnitus
- Registration Number
- JPRN-jRCTs041220129
- Lead Sponsor
- Takakura Hiromasa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
1) The first onset chronic, persistent, and subjective unilateral tinnitus whose duration is 2-18 months.
2) Age-related sensorineural hearing loss, with a hearing loss no less than 30 dB at 4,000 Hz or at 8,000 Hz
3) THI-12 total score no less than 9 and TRSw total score no less than 12
4) HADS depression score no more than 14 and HADS anxiety score no more than 14
a. Person with past or current malignant tumor
b. Person with severe comorbidities, such as heart, liver, kidney, blood, or mental diseases
c. Person with allergy against medicine or the test food
d. Pregnant, unwilling to practice contraception during the study, or lactating female
e. Person with middle ear disease
f. Person with conductive hearing loss, mixed hearing loss, or sensorineural hearing loss excluding age-related hearing loss
g. Person taking drug or supplement which contains nicotinamide, nicotinic acid, or NMN
h. Person who is not judged as not qualified by the medical doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method